Tropheryma whipplei glycosylation in the pathophysiologic profile of whipple's disease

Journal of Infectious Diseases

Volumn 199, Issue 7, 2009, Pages 1043-1052

  Bonhomme, Cyrille Y ^a   Renesto, Patricia ^a   Desnues, Benoît ^a   Ghigo, Eric ^a   Lepidi, Hubert ^a   Fourquet, Patrick ^b   Fenollar, Florence ^a   Henrissat, Bernard ^a   Mege, Jean Louis ^a   Raoult, Didier ^a,c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSERM   (France)

^c AIX MARSEILLE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; GLYCOPROTEIN; GLYCOSYLATED PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG; WNT1 INDUCIBLE SIGNALING PATHWAY PROTEIN;

ARTICLE; BACTERIUM CARRIER; BIOFILM; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; INTESTINE LIPODYSTROPHY; MACROPHAGE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; TROPHERYMA WHIPPELII; UPREGULATION; CARBOHYDRATE METABOLISM; CHEMISTRY; GLYCOSYLATION; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; PROTEIN PROCESSING; TROPHERYMA;

BIOFILMS; CARBOHYDRATE METABOLISM; GENE EXPRESSION REGULATION, BACTERIAL; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; MACROPHAGES; PROTEIN PROCESSING, POST-TRANSLATIONAL; TROPHERYMA; WHIPPLE DISEASE;

EID: 65549099539     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/597277     Document Type: Article

References (38)

1. La Scola B, Fenollar F, Fournier PE, Altwegg M, Mallet MN, Raoult D. Description of Tropheryma whipplei gen. nov., sp. nov., the Whipple's disease bacillus. Int J Syst Evol Microbiol 2001; 51:1471-9.
2. Fenollar F, Puéchal X, Raoult D. Whipple's disease. N Engl J Med 2007; 356:55-66.
3. Wilson KH, Blitchington R, Frothingham R, Wilson JA. Phylogeny of the Whipple's-disease-associated bacterium. Lancet 1991; 338:474-5.
4. Relman DA, Schmidt TM, MacDermott RP, Falkow S. Identification of the uncultured bacillus of Whipple's disease. N Engl J Med 1992; 327: 293-301.
5. Whipple GH.Ahitherto undescribed disease characterized anatomically by deposits of fat and fatty acids in the intestinal and mesenteric lymphatic tissues. Bull Johns Hopkins Hosp 1907; 18:382-91.
6. Raoult D, Birg ML, La Scola B, et al. Cultivation of the bacillus of Whipple's disease. N Engl J Med 2000; 342:620-5.
7. La Scola B, Fenollar F, Fournier PE, Altwegg M, Mallet MN, Raoult D. Description of Tropheryma whipplei gen. nov., sp. nov., the Whipple's disease bacillus. Int J Syst Evol Microbiol 2001; 51:1471-9.
8. Bentley SD, Maiwald M, Murphy LD, et al. Sequencing and analysis of the genome of the Whipple's disease bacterium Tropheryma whipplei. Lancet 2003; 361:637-44.
9. Renesto P, Crapoulet N, Ogata H, et al. Genome-based design of a cellfree culture medium for Tropheryma whipplei. Lancet 2003; 362:447-9.
10. Black-Schaffer B. The tinctoral demonstration of a glycoprotein in Whipple's disease. Proc Soc Exp Biol Med 1949; 72:225-7.
11. Schöniger-Hekele M, Petermann D, Weber B, Müller C. Tropheryma whipplei in the environment: survey of sewage plant influxes and sewage plant workers. Appl Environ Microbiol 2007; 73:2033-5.
12. Fenollar F, Trani M, Davoust B, et al. Prevalence of asymptomatic Tropheryma whipplei carriage among human and nonhuman primates. J Infect Dis 2008; 197:880-7.
13. Romain F, Horn C, Pescher P, et al. Deglycosylation of the 45/47-kilodalton antigen complex of Mycobacterium tuberculosis decreases its capacity to elicit in vivo or in vitro cellular immune responses. Infect Immun 1999; 67:5567-72.
14. Villeneuve C, Etienne G, Abadie V, et al. Surface-exposed glycopeptidolipids of Mycobacterium smegmatis specifically inhibit the phagocytosis of mycobacteria by human macrophages: identification of a novel family of glycopeptidolipids. J Biol Chem 2003; 278:51291-300.
15. Murray GL, Attridge SR, Morona R. Altering the length of the lipopolysaccharide O antigen has an impact on the interaction of Salmonella enterica serovar Typhimurium with macrophages and complement. J Bacteriol 2006; 188:2735-9.
16. Fenollar F, Laouira S, Lepidi H, Rolain JM, Raoult D. Value of Tropheryma whipplei quantitative polymerase chain reaction assay for the diagnosis of Whipple disease: usefulness of saliva and stool specimens for first-line screening. Clin Infect Dis 2008; 47:659-67.
17. Fenollar F, Birg ML, Gauduchon V, Raoult D. Culture of Tropheryma whipplei from human samples: a 3-year experience (1999 to 2002). J Clin Microbiol 2003; 41:3816-22.
18. Ghigo E, Capo C, Aurouze M, et al. Survival of Tropheryma whipplei, the agent of Whipple's disease, requires phagosome acidification. Infect Immun 2002; 70:1501-6.
19. Kowalczewska M, Fenollar F, Lafitte D, Raoult D. Identification of candidate antigen in Whipple's disease using a serological proteomic approach. Proteomics 2006; 6:3294-305.
20. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996; 68:850-8.
21. Near KA, Stowers AW, Jankovic D, Kaslow DC. Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model. Infect Immun 2002; 70: 692-701.
22. Lepidi H, Fenollar F, Gerolami R, et al. Whipple's disease: immunospecific and quantitative immunohistochemical study of intestinal biopsy specimens. Hum Pathol 2003; 34:589-96.
23. Renesto P, Abergel C, Decloquement P, et al. Mimivirus giant particles incorporate a large fraction of anonymous and unique gene products. J Virol 2006; 80:11678-85.
24. Ghigo E, Imbert G, Capo C, Raoult D, Mege JL. Interleukin-4 induces Coxiella burnetii replication in human monocytes but not in macrophages. Ann N Y Acad Sci 2003; 990:450-9.
25. Desnues B, Raoult D, Mege JL. IL-16 is critical for Tropheryma whipplei replication in Whipple's disease. J Immunol 2005; 175:4575-82.
26. Desnues B, Ihrig M, Raoult D, Mege JL. Whipple's disease: a macrophage disease. Clin Vaccine Immunol 2006; 13:170-8.
27. Schneider T, Moos V, Loddenkemper C, Marth T, Fenollar F, Raoult D. Whipple's disease: new aspects of pathogenesis and treatment. Lancet Infect Dis 2008; 8:179-90.
28. Fenollar F, Fournier PE, Raoult D, Gérolami R, Lepidi H, Poyart C. Quantitative detection of Tropheryma whipplei DNA by real-time PCR. J Clin Microbiol 2002; 40:1119-20.
29. FatiGO. Babelomics Web site. Available at: http://babelomics.bioinfo. cipf.es. Accessed 21 January 2009.
30. CAZy: carbohydrate-active enzymes. Available at: http://www.cazy.org/. Accessed 21 January 2009.
31. Coutinho PM, Deleury E, Davies GJ, Henrissat B. An evolving hierarchical family classification for glycosyltransferases. J Mol Biol 2003; 328: 307-17.
32. Desnues B, Lepidi H, Raoult D, Mege JL. Whipple disease: intestinal infiltrating cells exhibit a transcriptional pattern of M2/alternatively activated macrophages. J Infect Dis 2005; 192:1642-6.
33. Fenouillet E, Gluckman JC, Bahraoui E. Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1. J Virol 1990; 64:2841-8.
34. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007; 7:255-66.
35. Bonhomme CJ, Renesto P, Nandi S, Lynn AM, Raoult D. Serological microarray for paradoxical diagnostic of Whipple's disease. Eur J Clin Microbiol Infect Dis 2008; 27:959-68.
36. van Kooyk Y, Geijtenbeek TB. DC-SIGN: escape mechanism for pathogens. Nat Rev Immunol 2003; 3:697-709.
37. Arellano-Reynoso B, Lapaque N, Salcedo S, et al. Cyclic -1,2-glucan is a Brucella virulence factor required for intracellular survival. Nat Immunol 2005; 6:618-25.
38. Benoit M, Fenollar F, Raoult D, Mege JL. Increased levels of circulating IL-16 and apoptosis markers are related to the activity of Whipple's disease. PLoS ONE 2007; 2:e494.